Have a feature idea you'd love to see implemented?
Let us know!
LSTA Lisata Therapeutics Inc
Price (delayed)
$3.57
Market cap
$29.97M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.51
Enterprise value
$10.46M
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely
Highlights
The net income has grown by 3.4% YoY
The EPS has plunged by 126% YoY but it has grown by 2.3% from the previous quarter
LSTA's equity is down by 36% YoY and by 12% from the previous quarter
Lisata Therapeutics's quick ratio has decreased by 28% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of LSTA
Market
Valuations
Earnings
Shares outstanding
8.39M
Market cap
$29.97M
Enterprise value
$10.46M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.88
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$20.74M
EBIT
-$21.54M
EBITDA
-$21.36M
Free cash flow
-$18.9M
Per share
Balance sheet
Liquidity
EPS
-$2.51
EPS diluted
-$2.51
Free cash flow per share
-$2.27
Book value per share
$4.05
Revenue per share
$0
TBVPS
$4.57
Total assets
$38.2M
Total liabilities
$4.76M
Debt
$0
Equity
$33.69M
Working capital
$33M
Debt to equity
0
Current ratio
8.03
Quick ratio
7.64
Net debt/EBITDA
0.91
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-45.2%
Return on equity
-50.9%
Return on invested capital
-124%
Return on capital employed
-64.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LSTA stock price
How has the Lisata Therapeutics stock price performed over time
Intraday
19.8%
1 week
14.06%
1 month
28.88%
1 year
28.42%
YTD
19.8%
QTD
19.8%
Financial performance
How have Lisata Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.49M
Net income
-$20.74M
Gross margin
N/A
Net margin
N/A
LSTA's operating income is up by 10% year-on-year and by 2.6% since the previous quarter
The net income has grown by 3.4% YoY
Growth
What is Lisata Therapeutics's growth rate over time
Valuation
What is Lisata Therapeutics stock price valuation
P/E
N/A
P/B
0.88
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 126% YoY but it has grown by 2.3% from the previous quarter
LSTA's equity is down by 36% YoY and by 12% from the previous quarter
LSTA's price to book (P/B) is 23% higher than its 5-year quarterly average of 0.6 and 23% higher than its last 4 quarters average of 0.6
Efficiency
How efficient is Lisata Therapeutics business performance
The return on invested capital has dropped by 58% year-on-year and by 8% since the previous quarter
LSTA's ROE is down by 41% YoY and by 10% from the previous quarter
Lisata Therapeutics's return on assets has decreased by 37% YoY and by 9% QoQ
Dividends
What is LSTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LSTA.
Financial health
How did Lisata Therapeutics financials performed over time
The company's total assets fell by 34% YoY and by 10% QoQ
LSTA's current ratio is down by 28% YoY and by 15% QoQ
The debt is 100% less than the equity
LSTA's equity is down by 36% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.